Compounds > 2-(4-morpholinoanilino)-6-cyclohexylaminopurine
Page last updated: 2024-09-05

2-(4-morpholinoanilino)-6-cyclohexylaminopurine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Machado-Neto, JA; Paiva, HH; Rego, EM; Rodrigues Alves, AP; Scheucher, PS; Simões, BP; Traina, F1

Other Studies

1 other study(ies) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Reversine triggers mitotic catastrophe and apoptosis in K562 cells.
    Leukemia research, 2016, Volume: 48

    Topics: Apoptosis; Aurora Kinase A; Aurora Kinase B; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Morpholines; Protein Kinase Inhibitors; Purines

2016